Stonebridge Capital Advisors’s Editas Medicine EDIT Stock Holding History

Stonebridge Capital Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-120	Closed	-$2K	–	942
2022 Q1	$2K	Hold	120	–	–	﹤0.01%	892
2021 Q4	$3K	Hold	120	–	–	﹤0.01%	798
2021 Q3	$5K	Sell	120 -120	-50%	-$6.58K	﹤0.01%	718
2021 Q2	$12K	Buy	240 +120	+100%	+$4.43K	﹤0.01%	714
2021 Q1	$5K	Buy	+120	New	+$6.84K	﹤0.01%	730
2020 Q3	–	Sell	-120	Closed	-$4K	–	330
2020 Q2	$4K	Hold	120	–	–	﹤0.01%	585
2020 Q1	$2K	Hold	120	–	–	﹤0.01%	639
2019 Q4	$4K	Hold	120	–	–	﹤0.01%	670
2019 Q3	$3K	Hold	120	–	–	﹤0.01%	662
2019 Q2	$3K	Buy	+120	New	+$2.86K	﹤0.01%	720

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Stonebridge Capital Advisors's EDIT Position: Q2 2022 in Review

Stonebridge Capital Advisors sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 120 shares — an estimated $2K sold.

Stonebridge Capital Advisors first reported a position in EDIT in Q2 2019 and held it in 10 quarters. The position peaked at $12K in Q2 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

Stonebridge Capital Advisors reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
Stonebridge Capital Advisors sold 120 Editas Medicine shares in Q2 2022, an estimated $2K.
Stonebridge Capital Advisors first reported a position in Editas Medicine in Q2 2019 and held it in 10 quarters.
Stonebridge Capital Advisors's Editas Medicine position peaked at $12K in Q2 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.